Please cancel claims 1-15, 17, 30-42, 44 and 56-78, without prejudice, and add new claims 79 and 80 as follows:

79. The method of claim 45, wherein the (-)-bupropion is administered by bolus injection.

80. The method of claim 45, wherein the (-)-bupropion is administered intrathecally.

Please amend the claims to read as follows:

16. A method for treating nicotine addiction in a human suffering from nicotine addiction, which comprises administering to said human a therapeutically effective amount of (-)-bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer.

18. The method of claim 16 wherein (-)-bupropion is administered intravenously, transdermally, or orally.

19. The method of claim 18 wherein (-)-bupropion is administered orally as a tablet or a capsule.

23. The method of claim 16 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is greater than approximately 90 % by weight of the total amount of bupropion.

24. The method of claim 16 wherein the amount of (-)- bupropion or a pharmaceutically acceptable salt thereof is 99 % or more by weight of the total amount of bupropion.

25. The method of claim 16 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.

26. The method according to claim 16 wherein (-)-bupropion is administered as the hydrochloride salt.

27. The method of claim 16 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

28. The method of claim 16 wherein said nicotine addiction is an addiction to smoking, or chewing tobacco.

29. The method of claim 16 wherein said administration is made one to four times a day.

43. A method for aiding smoking cessation in a human who smokes, which comprises administering to said human a therapeutically effective amount of (-)-bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer.

45. The method of claim 43 wherein (-)-bupropion is administered intravenously, transdermally, or orally.

47. The method of claim 43 wherein the amount administered is from about 10 mg to about 750 mg.

50. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is greater than approximately 90 % by weight of the total amount of bupropion.

51. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is 99 % or more by weight of the total amount of bupropion.

52. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer is administered together with a pharmaceutically acceptable carrier.

53. The method according to claim 43 wherein (-)-bupropion is administered as the hydrochloride salt.

54. The method of claim 43 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

55. The method according to claim 43, wherein said administration is made one to four times per day.